Crick — Clinical Intelligence Platform

Large-scale testing (Phase 3)Active Not RecruitingNCT04214067

What this trial is testing

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Who this might be right for

Endometrial Endometrioid AdenocarcinomaStage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

National Cancer Institute (NCI) 164

Results for “DMMR Cancer”

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care

Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection

KN035 for dMMR/MSI-H Advanced Solid Tumors

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer